16 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards? http://www.zacks.com/stock/news/405122/teva-teva-to-report-q1-earnings-whats-in-the-cards?cid=CS-ZC-FT-405122 Apr 29, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release http://www.zacks.com/stock/news/405780/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release?cid=CS-ZC-FT-405780 Apr 30, 2019 - Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Allergan (AGN) http://www.zacks.com/stock/news/408551/why-the-earnings-surprise-streak-could-continue-for-allergan-agn?cid=CS-ZC-FT-408551 May 03, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-ZC-FT-408333 May 03, 2019 - Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Allergan PLC (AGN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/07/allergan-plc-agn-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 May 07, 2019 - AGN earnings call for the period ending May 7, 2019.
Allergan Plc (AGN) CEO Brent Saunders on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4261019-allergan-plc-agn-ceo-brent-saunders-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 07, 2019 - Allergan Plc (NYSE:AGN) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Manisha Narasimhan - Vice President of Investor Relations and Strategic Initiatives Brent Saunder
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression http://www.zacks.com/stock/news/421714/allergans-agn-vraylar-gets-fda-nod-for-bipolar-depression?cid=CS-ZC-FT-421714 May 29, 2019 - Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 http://www.zacks.com/stock/news/425026/ironwood-initiates-dosing-in-mid-stage-study-for-md-7246?cid=CS-ZC-FT-425026 Jun 05, 2019 - Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

Pages: 12

Page 1